IP Library › Granted Patent US 8,282,911
Granted Patent B2
US 8,282,911 · App. 12/446,558 · Granted Oct 9, 2012

Implant material

Assignees: ETH Zürich; Universitat Zürich
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,282,911
App. No.
12/446,558
Granted
Oct 9, 2012
Kind
B2
Abstract

The present relates to the field of dental and bone surgery. In particular, the invention relates to fibrous pharmaceutical compositions; fibrous webs, yarns and woven fabrics of such pharmaceutical compositions; to implant material essentially consisting of fibrous pharmaceutical compositions; to the manufacturing and use of such fibers/webs/implant materials.

Claims (26)

1. A method of treatment of bone defects in dental related applications comprising the step of applying a composition

in the form of fibers said composition comprising:

i) one or more biodegradable polymers selected from the group consisting of polymers or copolymers of glycolic acid and/or lactic acid; and

ii) biodegradable inorganic nanoparticles consisting of XRD amorphous tricalcium phosphate (TCP) having a mean primary particle size below 500 nm; and

iii) optionally one or more pharmaceutically active ingredients and/or proteins

to a subject in need of such treatment.

2. A method for the treatment of bone defects in dental related applications comprising the step of applying a yarn said yarn consisting essentially of one or more fibers comprising:

i) one or more biodegradable polymers selected from the group consisting of polymers or copolymers of glycolic acid and/or lactic acid; and

ii) biodegradable inorganic nanoparticles consisting of XRD amorphous tricalcium phosphate (TCP) having a mean primary particle size below 500 nm; and

iii) optionally one or more pharmaceutically active ingredients and/or proteins

to a subject in need of such treatment.

3. A method for the treatment of bone defects in dental related applications comprising the step of applying a woven fabric said fabric

consisting essentially of fibers comprising i) one or more biodegradable polymers selected from the group consisting of polymers or copolymers of glycolic acid and/or lactic acid; and

ii) biodegradable inorganic nanoparticles consisting of XRD amorphous tricalcium phosphate (TCP) having a mean primary particle size below 500 nm; and

iii) optionally one or more pharmaceutically active ingredients and/or proteins

to a subject in need of such treatment.

4. A method for the treatment of bone defects in dental related applications comprising the step of applying a fibrous web, said web consisting essentially of fibers comprising i) one or more biodegradable polymers selected from the group consisting of polymers or copolymers of glycolic acid and/or lactic acid; and

ii) biodegradable inorganic nanoparticles consisting of XRD amorphous tricalcium phosphate (TCP) having a mean primary particle size below 500 nm; and

iii) optionally one or more pharmaceutically active ingredients and/or proteins

said web having a bulk density between 0.001-1.7 mg/cm 3 to a subject in need of such treatment.

5. The method according to claim 1 wherein said biodegradable inorganic nanoparticles consisting of XRD-amorphous TCP has some or all of the Ca-ions stoichiometrically replaced by one or more elements selected from the group comprising strontium, magnesium, sodium, potassium, bismuth, barium, gadolinium, europium, holmium, neodymium or praseodymium.

6. The method according to claim 1 wherein said biodegradable inorganic nanoparticles consisting of XRD-amorphous TCP has up to 0.5 mass-% of the Ca-ions replaced by Ag-ions.

7. The method according to claim 1 wherein said pharmaceutically active ingredients are selected from the group consisting of anti-microbiotic, anti-fungal, anti-inflammatory and immunosuppressive active ingredients.

8. The method according to claim 1 wherein said proteins are selected from the group of proteins that support bone healing and/or proteins that influence the differentiation of bone marrow stem cells to osteoclasts/osteoblasts.

9. The method according to claim 1 wherein at least 90 mass-% of said fibers have a diameter of 1-50 um.

10. The method according to claim 1 wherein said inorganic nanoparticles are homogeneously distributed within said biodegradable polymer.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME AND ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 022759 FRAME 0556. ASSIGNOR(S) HEREBY CONFIRMS THE NAME OF THE ASSIGNEE IS ETH ZURICH AND THE ADDRESS IS ETH TRANSFER, RAMISTRASSE 101, CH8092 ZURICH SWITZERLAND. Recorded Aug 28, 2012
From: STARK, JAN W; SCHNEIDER, OLIVER; LOHER, STEFAN; BRUNNER, TOBIAS; GRASS, ROBERT N; SIMONET, MARC; SCHMIDLIN, PATRICK
To: ETH ZURICH; UNIVERSITAT ZURICH
Reel/Frame 028859/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2009
From: STARK, JAN W.; SCHNEIDER, OLIVER; LOHER, STEFAN; BRUNNER, TOBIAS; GRASS, ROBERT N.; SIMONET, MARC; SCHMIDLIN, PATRICK
To: ETH ZURICH, ETH TRANSFER; UNIVERSITAT ZURICH
Reel/Frame 022759/0556 →
Continuity (1)
Related Publication 20100196440A1 · Aug 5, 2010